2,543 results on '"Mohty, M."'
Search Results
2. Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study
3. Allogreffe de cellules souches hématopoïétiques à partir d’un donneur haplo-identique*
4. The first steps towards a diverse and inclusive EBMT: a position paper
5. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
6. Metabolic syndrome and cardiovascular disease after haematopoietic cell transplantation (HCT) in adults: an EBMT cross-sectional non-interventional study
7. Impact of patient: donor HLA disparity on reduced-intensity-conditioned allogeneic stem cell transplants from HLA mismatched unrelated donors for AML: from the ALWP of the EBMT
8. Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
9. Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations
10. CO52 Comparative Analysis of Tabelecleucel Versus Standard of Care in Patients with EBV+ PTLD Following Hematopoietic Cell Transplant (HCT) or Solid Organ Transplant (SOT)
11. Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study
12. EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN–DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES
13. ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MAGNETISMM-3 STUDY
14. EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3
15. Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia
16. The impact of allogeneic-hematopoietic stem cell transplantation on patients' and close relatives' quality of life and relationships
17. Allogeneic Hematopoietic Stem Cell Transplantation in Solid Organ Transplant Recipients: A Retrospective, Multicenter Study of the EBMT
18. 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas
19. THE DEFIFRANCE REGISTRY STUDY: EFFECTIVENESS AND SAFETY OF DEFIBROTIDE IN PATIENTS WITH VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME FOLLOWING CHEMOTHERAPY
20. A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM): INITIAL SAFETY RESULTS FOR MAGNETISMM-3
21. Medication adherence among allogeneic hematopoietic stem cell transplant recipients: a pilot single-center study
22. Lymphocyte expansion after unrelated cord blood allogeneic stem cell transplantation in adults
23. Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the société Francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
24. Pre-transplant donor CD4− invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease
25. Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT
26. The EBMT–ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis
27. Inhibition of FLT3 in AML: a focus on sorafenib
28. Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT)
29. Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT
30. Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT
31. Total body irradiation/fludarabine versus busulfan/fludarabine as conditioning in all patients > 45 years in 1sr CR - a registry-based study by the ALWP of the EBMT [Abstract]
32. ALWP registry and achievements
33. Management of relapse after allogeneic HSCT for AML using reduced-intensity conditioning (RIC): a common study by the ALWP subcommittees on immunotherapy and RIC
34. Second allogeneic stem cell transplantation using reduced-intensity conditioning for acute myeloid leukaemia patients who relapsed following a first RIC allo-SCT: a survey from the Acute Leukaemia Working Party of EBMT [Abstract]
35. Management and outcome of myelodysplastic syndrome (MDS) and secondary acute myeloid leukaemia relapsing after allogeneic stem cell transplantation: a retrospective analysis on 888 patients by the MDS Subcommittee of the EBMT Chronic Leukaemia Working Party
36. RIC for AML: a decade later
37. Developing Centers Subcommittee: centre experience and results of allo-HSCT
38. Machine learning based predictive modeling for mortality 100 days post allogeneic hematopoietic stem cell transplantation (ALLO-HSCT) in acute leukemia: an EBMT-Acute Leukemia Working Party (ALWP) registry study [Abstract]
39. Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation (HSCT): a survey on behalf of the ALWP of the EBMT [Abstract]
40. Heterogeneity of myeloablative total body irradiation techniques in current clinical practice. A survey of Acute Leukemia Working Party of the EBMT [Abstract]
41. Allogeneic stem cell transplantation for acute myeloid leukemia with normal cytogenetics (CN-AML): outcome, risk factors and role of molecular subgroups in 1006 patients - a report from the Acute Leukemia Working Party of EBMT [Abstract]
42. Factors determining the kinetics of disease relapse after allogeneic stem cell transplantation (allo-SCT) for acute myeloid leukaemia (AML): a survey from the Acute Leukaemia Working Party of the EBMT [Abstract]
43. Unmanipulated haploidentical stem cell transplantation after reduced intensity or ablative conditioning regimen for the treatment of acute leukemia: a report from the acute leukemia working party of the EBMT [Abstract]
44. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT
45. Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation
46. Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation
47. Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party
48. The impact of total body irradiation on the outcome of patients with follicular lymphoma treated with autologous stem-cell transplantation in the modern era: a retrospective study of the EBMT Lymphoma Working Party
49. Occurrence of graft‐versus‐host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT
50. What is the outcome in patients with acute leukaemia who survive severe acute graft‐versus‐host disease?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.